Zolmitriptan

佐米曲普坦

Report date: 2024/04/11 10:47:40
NME

Base Information

Drug NameZolmitriptan
Drug Alias NameZomig-ZMT佐米曲坦Zolmitriptanum佐米普坦Qtrypta +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 1b (5-HT1b) receptor agonistsSerotonin 1a (5-HT1a) receptor agonistsSerotonin 1d (5-HT1d) receptor agonists
TargetsSerotonin 1b (5-HT1b) receptorSerotonin 1a (5-HT1a) receptorSerotonin 1d (5-HT1d) receptor
Therapy Area/IndicationsMigraine Disorders
Global Approved IndicationsMigraine Disorders
Approved Indications in ChinaMigraine Disorders
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date1997/03/01
Country/TerritoryUnited StatesUnited KingdomMainland China +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesSawai Pharmaceutical Co Ltd +[2] 
Inactive CompaniesAcorda TherapeuticsAstrazeneca PlcIpr Pharmaceuticals Inc +[5] 
Active IndicationsMigraine Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN02CC03
Related LinksWikipediaDrugBankKEGG